Pancreatic Cancer Research

ResearcherQueensland University of TechnologyActive in the last 2 years

Amir Avan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4968-0962; OpenAlex author ID A5071764880. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
42
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers

Papers 19

  1. Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-024-04712-1↗
  2. Machine learning algorithms and biomarkers identification for pancreatic cancer diagnosis using multi-omics data integration. Last author DOI 10.1016/j.prp.2024.155602↗
  3. Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer. Co-author DOI 10.1080/15257770.2024.2319215↗
  4. Microbiome as a biomarker and therapeutic target in pancreatic cancer. Last author DOI 10.1186/s12866-023-03166-4↗
  5. Down regulation of Cathepsin W is associated with poor prognosis in pancreatic cancer. Last author DOI 10.1038/s41598-023-42928-y↗
  6. Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3390/cancers15030628↗
  7. New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4. Co-author DOI 10.3390/molecules27051682↗
  8. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer. Last author DOI 10.1016/j.lfs.2021.119118↗
  9. PNU-74654 enhanced the antiproliferative activity of gemcitabine via targeting Wnt/β-catenin Pathway in Pancreatic cancer Last author DOI 10.21203/rs.3.rs-881431/v1↗
  10. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3390/cancers13174389↗
  11. A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells. Co-author DOI 10.3390/molecules27010019↗
  12. Targeted therapies in pancreatic cancer: Promises and failures. Last author DOI 10.1002/jcb.26284↗
  13. Therapeutic potential of targeting the Wnt/β-catenin pathway in the treatment of pancreatic cancer. Last author DOI 10.1002/jcb.27835↗
  14. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2174/1381612825666190110145855↗
  15. Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives. Last author DOI 10.1002/jcb.25897↗
  16. Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies. Last author DOI 10.1002/jcp.25798↗
  17. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer. Last author DOI 10.2174/0929867324666170206142658↗
  18. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer. Last author DOI 10.2174/1381612822666160817095047↗
  19. Pharmacogenomic modeling in pancreatic cancer—letter. Co-author DOI 10.1158/1078-0432.ccr-14-2951↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Giovannetti · 7 shared papers, 2021–2024 · strength 1.23
  2. Gordon A. Ferns · 7 shared papers, 2017–2024 · strength 0.84
  3. Majid Khazaei · 7 shared papers, 2017–2024 · strength 0.82
  4. Godefridus J. Peters · 3 shared papers, 2021–2024 · strength 0.55
  5. Fatemeh Khojasteh‐Leylakoohi · 3 shared papers, 2023–2024 · strength 0.54
  6. Majid Ghayour‐Mobarhan · 5 shared papers, 2015–2024 · strength 0.54
  7. Luca Morelli · 2 shared papers, 2023–2024 · strength 0.38
  8. Mina Maftouh · 5 shared papers, 2015–2017 · strength 0.35
  9. Ghazaleh Pourali · 2 shared papers, 2023–2024 · strength 0.32
  10. Mahrou Vahabi · 1 shared paper, 2024 · strength 0.28
  11. Geng Xu · 1 shared paper, 2024 · strength 0.28
  12. Daniela Carbone · 2 shared papers, 2021 · strength 0.27
  13. Camilla Pecoraro · 2 shared papers, 2021 · strength 0.27
  14. Patrizia Diana · 2 shared papers, 2021 · strength 0.27
  15. Arian Karimi Rouzbahani · 1 shared paper, 2024 · strength 0.24
  16. Sofia Martins Sousa · 1 shared paper, 2024 · strength 0.22
  17. Cristina P. R. Xavier · 1 shared paper, 2024 · strength 0.22
  18. M. Helena Vasconcelos · 1 shared paper, 2024 · strength 0.22
  19. Mina Hosseini · 3 shared papers, 2016–2017 · strength 0.21
  20. Annalisa Comandatore · 1 shared paper, 2023 · strength 0.16
  21. Thomas Schmidt · 1 shared paper, 2023 · strength 0.16
  22. Erik H.J. Danen · 1 shared paper, 2023 · strength 0.16
  23. Cecilia Bergonzini · 1 shared paper, 2023 · strength 0.16
  24. Mjriam Capula · 1 shared paper, 2023 · strength 0.16
  25. Alessandro Gregori · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.